science
Eli Lilly Provided Experimental Obesity Drug to One Patient via FDA Compassionate-Use Program
STAT reported that Eli Lilly supplied its experimental obesity drug retatrutide to a single 79-year-old man via the FDA’s compassionate-use pathway in April. The access drew attention from top health officials. Three sources requested anonymity citing fear of reprisals.
StatAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Eli Lilly provided its experimental obesity drug retatrutide to one patient through the FDA’s compassionate-use program in April. The patient was a 79-year-old man at the time of the request, according to three sources familiar with the matter. Those sources told STAT the access drew the interest of top health officials, indicating the recipient was well connected.
Retatrutide is an experimental therapy developed by Eli Lilly. The drug has demonstrated bariatric-surgery levels of weight loss in clinical testing. The three sources requested anonymity due to fear of reprisals.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationLimited · 1 source
